Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis

Publisher： Karger

E-ISSN： 1421-9670|43|4|229-236

ISSN： 0250-8095

Source： American Journal of Nephrology, Vol.43, Iss.4, 2016-04, pp. : 229-236

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rivaroxaban in Chronic Hemodialysis Patients

By  

American Journal of Nephrology, Vol. 43, Iss. 4, 2016-04 ,pp. : 227-228

Karger

Access to resources Recommend Favorite

Pharmacokinetics of Cetirizine in Chronic Hemodialysis Patients: Multiple-Dose Study

By  

Nephron, Vol. 89, Iss. 1, 2001-08 ,pp. : 101-104

Karger

Access to resources Recommend Favorite

Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error

By  

American Journal of Nephrology, Vol. 44, Iss. 2, 2016-08 ,pp. : 169-169

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Single Bolus Anticoagulation with Enoxaparin for Chronic Hemodialysis. Results of an Open-Label Post-Certification Study

By  

Kidney and Blood Pressure Research, Vol. 27, Iss. 4, 2004-09 ,pp. : 211-217

Karger

Access to resources Recommend Favorite

Effect of Dialysis Dose on Nutritional Status of Children on Chronic Hemodialysis

By  

Nephron, Vol. 88, Iss. 3, 2001-06 ,pp. : 273-275

Karger

Access to resources Recommend Favorite